NMN at Crossroads: What Brands and Consumers Need to Know in 2025

When will the FDA finally respond to the NMN ban? With the July 31 deadline just around the corner, the future of Nicotinamide Mononucleotide (NMN) in the US remains uncertain, leaving many people unsure of what comes next.

Across the Atlantic, the European Union is moving steadily toward recognizing NMN as a novel food through the dossier process. But in the US, the picture is way more complicated. The FDA’s move to ban NMN from being sold as a dietary supplement has stirred confusion and concern across the health industry. Brands and manufacturers are scrambling for answers, and consumers—many of whom have come to trust NMN as part of their wellness routine—are wondering why “The FDA has banned NMN” and what it means for future NAD+ supplement selection.

So, what’s next for NMN in America? How might this impact those who see it as a valuable tool for healthy aging? In this article, we’ll break down the regulatory back-and-forth, look at the science behind NMN, and explore where things might be headed—from possible legal resolutions to emerging alternatives.

Why does the FDA ban NMN?

The restriction on NMN is not related to safety issues but stems from the FDA’s regulations designed to protect drug development pathways (commonly referred to as the IND preclusion clause). And it’s not yet de facto banned from all selling channels as legal questions remain under review..

“An article that is authorized for investigation as a new drug, antibiotic, or biological for which substantial clinical investigations have been instituted and for which the existence of such investigations has been made public, is not a dietary supplement unless the article was marketed as a dietary supplement or as a food before such authorization.”

In the NMN case, the FDA’s attitude towards NMN sparked significantly more intense controversy. NMN had been sold as a dietary supplement for years before any drug investigation emerged. NMN manufacturers argue that the FDA’s decision disregards NMN’s established market presence and lacks transparency in distinguishing between drugs and supplements.

The most recent updates are on October 24, 2024, a federal court issued a stay, effectively pausing legal proceedings while the FDA reviews the citizen petition regarding NMN. Underlying that, NMN products are still available and continue to be sold without immediate regulatory concerns as long as they comply with existing regulations.

This situation is not without precedent. In 2018, a similar case emerged with N-Acetyl-L-Cysteine (NAC), which was also removed from the supplement market under the same provision. That decision was later revisited following public and industry feedback.

NMN Clinical Studies: What the Research Says

One of the most notable clinical studies on NMN comes from UTHEVER® NMN, the world’s first clinically proven NMN brand developed by EffePharm. In a randomized, double-blind, placebo-controlled human trial, UTHEVER^® NMN demonstrated significant improvements in NAD+ levels, muscle endurance, and insulin sensitivity after 60 days of supplementation. Participants also reported increased energy levels and overall well-being, with no safety concerns.

Beyond UTHEVER^® NMN, other studies have shown NMN’s potential in supporting NAD+ levels, improving mitochondrial function, promoting healthy aging markers, and reducing fatigue. While the body of evidence is still growing, the current data suggests that NMN is a promising candidate for further research in the areas of metabolic health, age-related decline, and cellular energy support.

Read more on NMN clinical studies in our NMN white paper.

NMNH (Reduced NMN): Exploring Alternatives

With the regulatory future of NMN still uncertain, an increasing number of consumers are turning to promising alternatives that offer comparable benefits. One such option is NMNH (Dihydrated Nicotinamide Mononucleotide, also known as reduced nicotinamide mononucleotide), a next-generation NAD+ enhancer that’s quickly gaining attention for its ability to support NAD+ levels effectively.

UthPeak^® NMNH has already achieved Self-GRAS (Generally Recognized as Safe) status, reinforcing its safety and suitability for use in dietary supplements and fortified foods. Adding to its credibility, UthPeak® has recently completed its Phase I clinical study, marking a key milestone in its development.

Read more on NMNH’s 10X NAD+ enhancement ability.

The Future of NMN in the US: Three Possible Scenarios

The future of NMN supplements in the US hinges on the FDA’s next moves. Three potential scenarios could unfold:

1. Permanent Availability: The FDA could reverse its ban on NMN, allowing it to be sold as a dietary supplement, much like the case with NAC.
2. Temporary Availability: If the FDA does not respond by the specified deadline of July 31, NMN may remain available temporarily. This would provide an opportunity for further research and advocacy.
3. Formal Ban: If NMN is officially banned, all domestic sales within the US would be restricted. This situation could lead consumers to seek NMN from international sources or consider alternative supplements, such as reduced NMN.

As the NMN’s legal status in the US remains uncertain, ongoing clinical research and health industry efforts continue to shape its future in the landscape.

As the debate continues, consumers should stay informed on the research updates. If you are interested in incorporating ingredients like NMN into your health routine, always consult with healthcare professionals regarding dosage and any other health-related concerns. Remember, always consider trusted options like UTHEVER® NMN or UthPeak® NMNH for safe, adequate NAD+ support.

Contact us to stay informed about NMN’s legal status worldwide and discover top alternatives to support your top-notch healthy supplement lines.